Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425323 | 0.93 | TYMP (0.30) | TYMP | |
| SCHEMBL5808874 | 0.93 | ALDH1A1 (0.35) | TYMP | |
| SCHEMBL5960582 | 0.91 | — | — | |
| SCHEMBL6446235 | 0.89 | PSMB5 (0.33) | TYMP | |
| SCHEMBL4796621 | 0.87 | PSMB5 (0.32) | TYMP | |
| SCHEMBL3082501 | 0.87 | PSMB5 (0.32) | TYMP | |
| SCHEMBL3796622 | 0.87 | PSMB5 (0.32) | TYMP | |
| SCHEMBL13858383 | 0.87 | PSMB5 (0.32) | TYMP | |
| SCHEMBL7402470 | 0.87 | PSMB5 (0.32) | TYMP | |
| SCHEMBL3343469 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDRENS HOSPITAL MED CT (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-02-18 | — | — | US | disclosed |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10420748-B2 | Methods of treatment associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2019-09-24 | — | — | US | disclosed |
| EP-2814494-B1 | USE OF SMALL MOLECULE INHIBITORS TARGETING THE INTERACTION BETWEEN RAC GTPASE AND P67 (PHOX) | CHILDRENS HOSPITAL MED CT (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2488486-B1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARM INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-12-27 | — | — | US | disclosed |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20080044472-A1 | Photoresponsive Hydrogels | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2008-02-21 | — | — | US | disclosed |
| US-20080019942-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2008005511-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006137840-A2 | DIPHENYL ETHER ANTIMICROBIAL COMPOUNDS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| US-20060041025-A1 | 5-Alkyl (4-26 carbon atoms)-2-phenoxyphenols; enoyl reductase enzyme inhibitor; drug resistance; side-effect reduction; nicrobiocides; carriers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
| US-20050197375-A1 | Use of benzimidazole analogs in the treatment of cell proliferation | AVANIR PHARMACEUTICALS | 2005-09-08 | — | — | US | disclosed |
| WO-2005072334-A2 | PHOTORESPONSIVE HYDROGELS | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | TYMP 1111/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | TYMP 446/4885 |
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | TYMP 1111/4885 |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | TYMP 1111/4885 |
| US-20050197375-A1 | Use of benzimidazole analogs in the treatment of cell proliferation | MKI67, CCNI, CDKN1A | TYMP 38/4885 |
| US-10221151-B2 | Use of small molecule inhibitors targeting EYA tyrosine phosphatase | EYA2, EYA3, PTPRO | TYMP 871/4885 |
| US-20080044472-A1 | Photoresponsive Hydrogels | HSP90AA1, HSF1, HSP90AB2P | TYMP 1382/4885 |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | TYMP 1111/4885 |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | EYA3, EYA2, LIG3 | TYMP 224/4885 |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | TYMP 1111/4885 |
| US-20060041025-A1 | 5-Alkyl (4-26 carbon atoms)-2-phenoxyphenols; enoyl reductase enzyme inhibitor; drug resistance; side-effect reduction; nicrobiocides; carriers | CBR1, CBR3, FAR1 | TYMP 4361/4885 |
| US-20060074076-A1 | Heterocyclic derivatives for modulation of calcium channels | CACNA1D, ORAI1, CACNA1C | TYMP 4360/4885 |
| US-10420748-B2 | Methods of treatment associated with the granulocyte colony-stimulating factor receptor | CSF3R, CSF1R, OGFR | TYMP 528/4885 |
| US-20080019942-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, GTF3C3 | TYMP 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.